

1 **Title: Clinical evaluation of an automated, rapid mariPOC<sup>®</sup> antigen test in screening of symptomatics and**  
2 **asymptomatics for SARS-CoV-2 infections**

3

4 **Authors:** Marianne Gunell<sup>1,2#</sup>, Kaisa Rantasärkkä<sup>1</sup>, Rita Arjonen<sup>3</sup>, Antti Sandén<sup>3</sup>, Tytti Vuorinen<sup>1,2</sup>

5 **Affiliations:** <sup>1</sup> Clinical Microbiology, Laboratory Division, Turku University Hospital; <sup>2</sup> Institute of  
6 Biomedicine, University of Turku; <sup>3</sup> Kaarina City Health Care Center

7

8 **Abstract**

9 A novel automated mariPOC<sup>®</sup> SARS-CoV-2 antigen test was evaluated in a Health care center laboratory  
10 among symptomatic and asymptomatic individuals seeking SARS-CoV-2 testing. According to the national  
11 testing strategy, RT-PCR was used as a reference method. A total of 962 subjects were included in this  
12 study, 4.8% (46/962) of their samples were SARS-CoV-2 RT-PCR positive, and 87% (40/46) of these were  
13 from symptomatics. Among the symptomatics, the overall sensitivity of the mariPOC<sup>®</sup> SARS-CoV-2 test was  
14 82.5% (33/40), though the sensitivity increased to 97.1% (33/34) in samples with a Ct value <30. The  
15 mariPOC<sup>®</sup> SARS-CoV-2 test detected 2/6 PCR positive samples among the asymptomatics, four cases that  
16 remained antigen test negative had Ct values between 28 and 36. The specificity of the mariPOC<sup>®</sup> SARS-  
17 CoV-2 test was 100% (916/916). The evaluation showed that the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test is  
18 very sensitive and specific for the detection of individuals who most probably are contagious.

19

20

21

22

23

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 24 Introduction

25 The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)  
26 has been a significant burden for both society and the carrying capacity of health care since late 2019 [1]  
27 when this emerging virus was initially recognized in Wuhan, China. SARS-CoV-2 can mutate into the new  
28 emerging variants escaping immunity, and it can in addition to symptomatic infections, manifest as both  
29 asymptomatic and presymptomatic infections, and thus the virus has spread efficiently all over the world.  
30 According to a simulation model made by US CDC, transmission from asymptomatic individuals, including  
31 presymptomatic individuals and those who never develop symptoms, is estimated to account for more  
32 than half of all SARS-CoV-2 infections [2]. To prevent the spread of infection there is a need for rapid and  
33 accurate diagnostic tests, which detect contagious individuals irrespective of their presence or absence of  
34 COVID-19 symptoms.

35 PCR-based methods, especially RT-PCR is up to date considered the cornerstone for fighting against the  
36 pandemic [3,4]. However, large-scale RT-PCR testing, although with excellent sensitivity and analytical  
37 specificity, also has some major disadvantages such as long turnaround time as well as the requirement for  
38 sophisticated equipment and highly trained personnel. Furthermore, it has been proposed that a positive  
39 PCR result may not correlate with infectivity [5], as viral nucleic acids can be detected for a long time after  
40 the acute infection, without the presence of infectious and actively replicating SARS-CoV-2 virus [6- 12]. As  
41 the COVID-19 continues to be a worldwide threat, there is a continuous demand for rapid testing of SARS-  
42 CoV-2. Several inexpensive and easy-to-use rapid antigen tests have been developed [13]. Rapid antigen  
43 tests have been shown to correlate more accurately with SARS-CoV-2 viral culture than RT-PCR [12], thus  
44 also controversial results have been reported [5,14]. Rapid antigen testing of SARS-CoV-2 as a  
45 complementary diagnostic method alongside RT-PCR testing has been recently accepted [3,4,15]. ECDC has  
46 recommended the use of antigen tests for SARS-CoV-2 diagnostics with a sensitivity of at least 80% and  
47 specificity of at least 97% [16].

48 The technique of the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test (ArcDia International Ltd, Finland) is based on  
49 the detection of conserved SARS-CoV-2 nucleocapsid protein with specific monoclonal antibodies. Most  
50 positive test results are reported after 20 minutes and final results within 55 minutes [17,18]. The mariPOC<sup>®</sup>  
51 platform is an automated and random access test system that enables simple and quick workflow, high  
52 capacity testing, as well as objective result readout. On the platform, the SARS-CoV-2 test is also available  
53 as part of syndromic multianalyte tests Quick Flu+ (20 minutes results only) and Respi+ (final results in two  
54 hours).

55 In the present study, the clinical performance of the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test was  
56 prospectively evaluated in samples collected in the city of Kaarina, Southwest Finland during spring 2021.  
57 Results of on-site testing were compared with central laboratory RT-PCR results to estimate the clinical  
58 sensitivity and specificity of the mariPOC<sup>®</sup> SARS-CoV-2 antigen test.

## 59 **Materials and methods**

### 60 **Study population and specimen collection**

61 An automated mariPOC<sup>®</sup> SARS-CoV-2 antigen test system was verified for use in the Kaarina city Health care  
62 center laboratory for SARS-CoV-2 diagnostics. Verification was conducted between February and May 2021,  
63 when the prevalence of SARS-CoV-2 positivity among the tested samples in South-West Finland was  
64 approximately 4%. The main circulating SARS-CoV-2 variant in the geographical area during the study  
65 period was the Alpha variant (B.1.1.7). At the time, according to the Finnish national COVID-19 hybrid  
66 strategy, all individuals having respiratory symptoms as well as those exposed to SARS-CoV-2 were tested  
67 and screened, respectively, for SARS-CoV-2.

68 Two consecutive nasopharyngeal swab (NPS) specimens were obtained from a total of 939 subjects after  
69 collecting oral consent. Age, gender, symptoms, and time from the symptom onset were collected from  
70 each subject. Of the subjects, 881 had COVID-19-like symptoms and 58 were asymptomatic. The first  
71 collected NPS specimen was placed into a viral transport medium (VTM, Bioer sample preservative fluid,  
72 BSC82X1-A1) and transported to Turku University Hospital for SARS-CoV-2 RT-PCR testing (cohort 1). The

73 Clinical microbiology laboratory at Turku University Hospital is the primary laboratory responsible for SARS-  
74 CoV-2 testing in the Hospital District of Southwest Finland. The second NPS specimen was stored, if needed  
75 before mariPOC<sup>®</sup> analysis, at +4°C in the health care center laboratory.

76 During the study period, the prevalence of SARS-CoV-2 in the target population was very low. It became  
77 soon obvious that based on national verification guidelines of microbiological CE marketed tests [19], a  
78 sufficient amount of positive samples to assess test accuracy before introduction in clinical diagnostics,  
79 could not be collected in a reasonable time. Therefore, the protocol for sample collection and analysis was  
80 altered. Thereafter, together with the strategy implemented in cohort 1, the primary screening of SARS-  
81 CoV-2 positive samples was performed with RT-PCR in the Clinical Microbiology laboratory. PCR positive  
82 samples were stored at -20 °C and later analyzed by mariPOC<sup>®</sup> antigen test in the Health care center  
83 laboratory (cohort 2). Of the samples in cohort 2, two were omitted from the analysis due to improper  
84 handling of the samples before being aliquotted for mariPOC<sup>®</sup> testing and thus 23 consecutive SARS-CoV-2  
85 positive samples of which six were taken from asymptomatic subjects, were included. For this cohort, NPS  
86 specimens were suspended into 2 ml VTM (VACUETTE<sup>®</sup> Virus Stabilization tube, 456162) for the primary  
87 screening of SARS-CoV-2 by RT-PCR. In contrast to Bioer tube, VACUETTE VTM was found to be applicable  
88 also in mariPOC<sup>®</sup> antigen analysis.

#### 89 ***In-house SARS-CoV-2 RT-PCR***

90 SARS-CoV-2 RT-PCR from NPS specimens was performed in the Clinical microbiology laboratory at Turku  
91 University Hospital. Nucleic acid extraction was performed with Chemagic™ 360 extractor with Viral  
92 DNA/RNA 300 Kit H96 (PerkinElmer, Turku, Finland). The in-house RT-PCR test used for SARS-CoV-2 E gene  
93 detection was based on the Charité protocol by Corman et al. [20]. The human  $\beta$ -actin gene was used as an  
94 internal control (IC) in the test. Final primer concentrations were 400 nM for E gene primers and 200 nM for  
95 E gene probe, 40nM for  $\beta$ -actin primers bA-F926 5'-TTGCCGACAGGATGCAGAA-3' and bA-P954 5'-  
96 TGCCCTGGCACCCAGCACAA-3' and 80 nM for probe bA-R1001 5'-HEX-TCAGGAGGAGCAATGATCTTGAT-BHQ-  
97 1-3'. SensiFAST™ Probe No-ROX One-Step Kit (Meridian Bioscience, USA) was used for RT-PCR. Each 25  $\mu$ L

98 reaction consisted of 12.5  $\mu$ L of 2X SensiFAST Probe One-Step mix, 1  $\mu$ L of E gene primers and 0.5  $\mu$ L of E  
99 gene probe, 0.1  $\mu$ L of  $\beta$ -actin primers, and 0.2  $\mu$ L  $\beta$ -actin probe, 0.2  $\mu$ L Reverse transcriptase, 0.4  $\mu$ L  
100 RiboSafe RNase Inhibitor and 9  $\mu$ L of extracted RNA template. Cycling conditions were 55 °C (10 min), 95 °C  
101 (3 min) followed by 45 cycles of 95 °C (15 s) and 58 °C (30 s) performed with BMS MIC analyzers (BMS  
102 Australia).

### 103 **mariPOC<sup>®</sup> SARS-CoV-2 antigen test**

104 The mariPOC<sup>®</sup> SARS-CoV-2 testing was performed in the on-site laboratory of Kaarina Health Care Center.  
105 NPS specimens from cohort 1 were suspended into 1.3 ml mariPOC<sup>®</sup> RTI sample buffer in sample tubes and  
106 analyzed with the mariPOC<sup>®</sup> test system according to the manufacturer`s instructions as soon as possible.  
107 The samples in cohort 2 were collected in VACUETTE VTM and stored at -20 °C after the primary SARS-CoV-  
108 2 PCR test and were further diluted 1:1 (0.65 ml+ 0.65 ml) with mariPOC<sup>®</sup> RTI sample buffer to gain the  
109 required sample volume for mariPOC<sup>®</sup> analysis. The VTM samples were diluted approximately 3-times more  
110 than in the dry swab procedure recommended by the mariPOC<sup>®</sup> manufacturer.

### 111 **Statistical analysis**

112 The mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test sensitivity, including 95% confidence intervals (CI), was  
113 determined using MedCalc Software [21].

## 114 **Results**

### 115 **Study population**

116 Demographic data of the population included in the mariPOC<sup>®</sup> rapid antigen test evaluation is presented in  
117 Table 1. Of the whole study population, 6.7% (64) were asymptomatic and 93.3% (898) had symptoms  
118 linked to COVID-19, such as sore throat, headache, fever, shortness of breath, and diarrhea.

### 119 **SARS-CoV-2 RT-PCR test results**

120 Totally, 962 samples were analyzed with RT-PCR. Of the tested samples, 46 (4.8%) were SARS-CoV-2  
121 positive with the RT-PCR method. Ct values for E gene amplification varied from 14.66 (high RNA load) to  
122 38.13 (low RNA load). Ct values <40 cycles for the E gene were interpreted as SARS-CoV-2 positive. In  
123 cohort 1, all 23 subjects with RT-PCR positivity had COVID-19 symptoms, whereas six of the 23 PCR positive  
124 samples in cohort 2 were from asymptomatic subjects and 17 subjects had COVID-19-like symptoms.

### 125 **Comparison of mariPOC<sup>®</sup> SARS-CoV-2 antigen test and RT-PCR test results**

126 The correlation of Ct values and mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test results among asymptomatic and  
127 symptomatic subjects are presented in Figure 1. Totally, 35 out of 46 (76.1%) of the SARS-CoV-2 RT-PCR  
128 positive samples were positive in the mariPOC<sup>®</sup> test (true positive). The overall sensitivity for symptomatic  
129 patients including both cohorts 1 and 2 was 97.1% (33/34) and 82.5% (33/40) when Ct values <30 and <40  
130 were used, respectively (Table 2). The mariPOC<sup>®</sup> test was positive for up to 10 days from the onset of  
131 symptoms.

132 In cohort 1, 18 PCR-positive samples were positive in the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test and five  
133 samples remained negative. Ct values for 18 true positive samples in the antigen detection varied from  
134 14.80 to 29.01 (Figure 1) and the mean duration of symptoms was 2.5 days (range 1–10 days). Of the five  
135 false-negative samples in the antigen detection, Ct values varied from 30.24 to 38.13, and the mean  
136 duration of symptoms was two days (range 0–5 days). The mariPOC<sup>®</sup> test sensitivity for cohort 1 was 78.3%  
137 (18/23, Table 2). When only samples with Ct values <30 were considered, the mariPOC<sup>®</sup> sensitivity in cohort  
138 1 within symptomatic subjects was 100.0% (18/18).

139 In cohort 2, 17 of the 23 PCR positive samples were mariPOC<sup>®</sup> SARS-CoV-2 test positive and six samples  
140 remained negative (Table 2). Four of the samples from cohort 2 were taken from patients whose second  
141 NPS specimen was also included in cohort 1. Of the six PCR positive samples that remained negative in the  
142 antigen detection, four were taken from asymptomatic patients and two have had only mild COVID-19  
143 symptoms for one or two days. Ct values for 17 true positive samples in the antigen detection varied from  
144 14.66 to 27.25 (Figure 1) and the mean duration of symptoms was 2.5 days (range 0–7 days). Ct values for

145 the false-negative samples in the antigen detection varied from 27.91 to 36.06, only two samples had Ct  
146 value <30 (Figure 1), and the mean duration of symptoms was 0.5 days (range 0–2 days). The sensitivity of  
147 the mariPOC<sup>®</sup> antigen test for cohort 2 was 73.9% (17/23), but when only symptomatic subjects were  
148 considered, the sensitivity was 88.2% (15/17, Table 2).

149 The results of the mariPOC<sup>®</sup> SARS-CoV-2 test reported after 20 minutes correlated well with the final  
150 results. Only three samples (one in cohort 1 and two in cohort 2) were negative after 20 minutes and  
151 turned into positive in final results at 55 minutes outcome. The Ct values for these positive samples varied  
152 from 24.43 to 28.04, and the duration of symptoms was 1–5 days.

## 153 Discussion

154 Early and accurate detection of SARS-CoV-2 infection is crucial for reducing virus transmission in the  
155 community. During the COVID-19 pandemic, the need for rapid testing has raised significantly and a high  
156 number of antigen tests have been introduced on the market. mariPOC<sup>®</sup> is a fully automated test system  
157 that enables the testing of up to 100 samples within a work shift at the sampling site. Over 90% of SARS-  
158 CoV-2 positive results are obtained in 20 minutes and low positive and negative results are reported after  
159 55 minutes. Hands-on time is short and analysis, as well as result reading, is automated. These properties  
160 make mariPOC<sup>®</sup> test systems suitable for use in medium and small-size volume laboratories and  
161 decentralized testing.

162 The evaluation of the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test to be used in a health care laboratory was  
163 performed in a medium-sized Finnish city representing adequate variation in social, ethnic, and age  
164 distribution of the population seeking COVID-19 testing in Finland. The SARS-CoV-2 positivity rate among  
165 the study population was 4.8%, determined by the RT-PCR method, which was well in correlation to the  
166 SARS-CoV-2 prevalence in the hospital district of Southwest Finland during spring 2021.

167 The sensitivities of antigen tests in different published studies have varied considerably due to differences  
168 in evaluated test products, study protocols, and patient cohorts [22,23]. The overall sensitivity of the  
169 mariPOC<sup>®</sup> antigen test in our evaluation was 76.1% which is in correlation with a recent meta-analysis

170 showing the overall pooled sensitivity of 72.1% of the antigen tests in publications fulfilling the criteria to  
171 be included in the meta-analysis [24]. When the results of cohorts 1 and 2 were assessed separately, the  
172 sensitivity in cohort 2 was lower (73.9%) than that in cohort 1 (78.3%). This could be explained by the fact  
173 that in cohort 2, four out of six false-negative samples were from asymptomatic subjects who most  
174 probably carry less SARS-CoV-2 virus than the symptomatic subjects. Threshold cycle (Ct) data from our RT-  
175 PCR was in line with this proposition. Furthermore, in cohort 2, the samples in VACUETTE tubes were  
176 diluted 3-times more for mariPOC<sup>®</sup> analysis compared to the recommended procedure of the manufacturer  
177 (NPS collected directly in mariPOC<sup>®</sup> RTI sample buffer). No false-positive findings were reported in this  
178 study.

179 The performance of antigen tests to detect SARS-CoV-2 is known to be highest during the first seven days  
180 from the appearance of symptoms [23,34] and most guidelines advise using rapid tests accordingly and in  
181 symptomatic subjects [4,16]. Our results show, that the overall sensitivity of 82.5% was reached when the  
182 sensitivity for samples obtained only from symptomatic individuals was assessed, thus showing the good  
183 performance of the mariPOC<sup>®</sup> SARS-CoV-2 test in diagnostic testing. While the number of positive samples  
184 among asymptomatic individuals was low (n=6), definitive conclusions about the use of the mariPOC<sup>®</sup>  
185 antigen test in detecting SARS-CoV-2 in asymptomatics cannot be drawn based on this study.

186 Infectivity of SARS-CoV-2 is associated with viral load and the lower Ct values in RT-PCR indicate higher viral  
187 load [25]. In the present study, we have shown that asymptomatic RT-PCR positive subjects had on average  
188 higher Ct values compared to subjects with symptoms and that antigen test sensitivity increases when Ct  
189 values decrease. When Ct <30 was used as a threshold, the sensitivity of the antigen test was 97.1% and  
190 even up to 100% when only symptomatic patients were included. Thus, the sensitivity of the mariPOC<sup>®</sup>  
191 rapid antigen test correlates better to RT-PCR Ct value than the patient symptom status or the intensity of  
192 symptoms, indicating that the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test recognizes well the subjects with  
193 contagious SARS-CoV-2 infection [26-28].



194 Results for the SARS-CoV-2 test of the mariPOC<sup>®</sup> test system are reported in two phases. At 20 minute  
195 outcome, most positive results are reported and due to the high specificity (here 100%), those results are  
196 reliable. At 55 minutes outcome also low positives and negatives are reported. In our study, 91.4% (32/35  
197 total mariPOC<sup>®</sup> antigen test positives) of positive samples were positive already at 20 minutes. Our  
198 prospective evaluation results of the mariPOC<sup>®</sup> test are well in line with those reported earlier from a  
199 retrospective study [18].

200 Although antigen tests have lower sensitivity compared to RT-PCR methods [25,29], to fight against COVID-  
201 19 pandemics both PCR and antigen tests are needed [5,14,15]. Especially in places where central hospital  
202 laboratory facilities are not available, shorter turnaround time and ease of use make antigen tests a  
203 powerful tool to prevent the spread of COVID-19. In addition, rapid antigen tests, such as automated  
204 mariPOC<sup>®</sup> SARS-CoV-2, could be a good alternative for large-scale screening of individuals at schools and  
205 workplaces and, therefore, help to prevent the spread of the COVID-19 in the community [28,30].

## 206 **Conclusions**

207 We conclude that the mariPOC<sup>®</sup> SARS-CoV-2 antigen test detected the majority of the samples with RT-PCR  
208 cycle threshold below 30 among symptomatic and asymptomatic subjects justifying its use for rapid  
209 detection of individuals who most probably are contagious. In addition, the mariPOC<sup>®</sup> test system is  
210 practicable in small and medium-size laboratories as well as health care centers to be used for rapid SARS-  
211 CoV-2 detection in symptomatics.

212

## 213 **Transparency declaration**

### 214 *Research permission and ethics declaration*

215 This study was approved by the Hospital District of Southwest Finland, research approval number  
216 T12/009/21. Ethical aspects of the study were considered and approved by Turku Clinical Research Centre  
217 (Turku CRC), no ethical committee review was required. Oral consent for sample collection was obtained

218 from each person. The samples were taken to apply a new test method for SARS-CoV-2 diagnosis in the  
219 laboratory and the results between the two tests were anonymously processed

#### 220 *Conflict of interest*

221 The authors declare no conflicts of interest regarding this study.

#### 222 *Funding*

223 ArcDia International Ltd provided mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen tests for the study, but the authors  
224 did not receive any fee for their authorship.

#### 225 *Acknowledgements*

226 Heta-Maija Manner and her colleagues (Kaarina city Health care center) are thanked for their skillful  
227 technical assistance with mariPOC<sup>®</sup> analyses.

228

#### 229 **References:**

230 1. Johns Hopkins University & Medicine. Coronavirus resource center. 2021. Available at:

231 <https://coronavirus.jhu.edu/> (2021)

232 2. Johansson MA, Quandelacy TM, Kada S, Prasad PV, Steele M, Brooks JT, Slayton RB, Biggerstaff M, Butler

233 JC. SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. JAMA Netw Open. 2021 Jan

234 4;4(1):e2035057. doi: 10.1001/jamanetworkopen.2020.35057. Erratum in: JAMA Netw Open. 2021 Feb

235 1;4(2):e211383. PMID: 33410879; PMCID: PMC7791354.

236 3. European Centre for Disease Prevention and Control/European Agency for Safety and Health at Work

237 (ECDC-EU:OSHA). Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2

238 in occupational settings. Available at: [Considerations on the use of rapid antigen detection \(including self-\)](#)

239 [tests for SARS-CoV-2 in occupational settings \(europa.eu\)](#) (2021)


- 240 4. World Health Organization (WHO). Laboratory testing for 2019 novel coronavirus (2019-nCoV) in  
241 suspected human cases: Interim guidance, 17 January 2020. Available at: [Laboratory testing of 2019 novel  
242 coronavirus \(2019-nCoV\) in suspected human cases: interim guidance, 17 January 2020 \(who.int\)](https://www.who.int/publications/m/item/laboratory-testing-of-2019-novel-coronavirus-2019-ncov-in-suspected-human-cases-interim-guidance-17-january-2020) (2020)
- 243 5. Binnicker MJ. Can Testing Predict SARS-CoV-2 Infectivity? The Potential for Certain Methods To Be  
244 Surrogates for Replication-Competent Virus. *J Clin Microbiol*. 2021 Oct 19;59(11):e0046921. doi:  
245 10.1128/JCM.00469-21. Epub 2021 Aug 4. PMID: 34346713; PMCID: PMC8525553.
- 246 6. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, Taylor J, Spicer K, Bardossy AC, Oakley  
247 LP, Tanwar S, Dyal JW, Harney J, Chisty Z, Bell JM, Methner M, Paul P, Carlson CM, McLaughlin HP,  
248 Thornburg N, Tong S, Tamin A, Tao Y, Uehara A, Harcourt J, Clark S, Brostrom-Smith C, Page LC, Kay M,  
249 Lewis J, Montgomery P, Stone ND, Clark TA, Honein MA, Duchin JS, Jernigan JA; Public Health–Seattle and  
250 King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 Infections and  
251 Transmission in a Skilled Nursing Facility. *N Engl J Med*. 2020 May 28;382(22):2081-2090. doi:  
252 10.1056/NEJMoa2008457. Epub 2020 Apr 24. PMID: 32329971; PMCID: PMC7200056.
- 253 7. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, Boodman C, Bello A, Hedley A, Schiffman Z,  
254 Doan K, Bastien N, Li Y, Van Caesele PG, Poliquin G. Predicting Infectious Severe Acute Respiratory  
255 Syndrome Coronavirus 2 From Diagnostic Samples. *Clin Infect Dis*. 2020 Dec 17;71(10):2663-2666. doi:  
256 10.1093/cid/ciaa638. PMID: 32442256; PMCID: PMC7314198.
- 257 8. La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, Gautret P, Raoult D. Viral RNA load  
258 as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious  
259 disease wards. *Eur J Clin Microbiol Infect Dis*. 2020 Jun;39(6):1059-1061. doi: 10.1007/s10096-020-03913-9.  
260 Epub 2020 Apr 27. PMID: 32342252; PMCID: PMC7185831.
- 261 9. Singanayagam A, Patel M, Charlett A, Lopez Bernal J, Saliba V, Ellis J, Ladhani S, Zambon M, Gopal R.  
262 Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,

- 263 England, January to May 2020. *Euro Surveill.* 2020 Aug;25(32):2001483. doi: 10.2807/1560-  
264 7917.ES.2020.25.32.2001483. Erratum in: *Euro Surveill.* 2021 Feb;26(7): PMID: 32794447; PMCID:  
265 PMC7427302.
- 266 10. Jaafar R, Aherfi S, Wurtz N, Grimaldier C, Van Hoang T, Colson P, Raoult D, La Scola B. Correlation  
267 Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures,  
268 Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. *Clin Infect Dis.* 2021 Jun  
269 1;72(11):e921. doi: 10.1093/cid/ciaa1491. Erratum in: *Clin Infect Dis.* 2021 Nov 2;73(9):1745. PMID:  
270 32986798; PMCID: PMC7543373.
- 271 11. Alexandersen S, Chamings A, Bhatta TR. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic  
272 samples are not an indicator of active replication. *Nat Commun.* 2020 Nov 27;11(1):6059. doi:  
273 10.1038/s41467-020-19883-7. PMID: 33247099; PMCID: PMC7695715.
- 274 12. Pekosz A, Parvu V, Li M, Andrews JC, Manabe YC, Kodosi S, Gary DS, Roger-Dalbert C, Leitch J, Cooper CK.  
275 Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute  
276 Respiratory Syndrome Coronavirus 2 Viral Culture. *Clin Infect Dis.* 2021 Nov 2;73(9):e2861-e2866. doi:  
277 10.1093/cid/ciaa1706. PMID: 33479756; PMCID: PMC7929138.
- 278 13. Foundation for Innovative New Diagnostics (FIND) SARS-CoV-2 Diagnostic pipeline. Available at:  
279 <https://www.finddx.org/covid-19/> (2021)
- 280 14. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. Evaluation of rapid antigen  
281 test for detection of SARS-CoV-2 virus. *J Clin Virol.* 2020 Aug;129:104500. doi: 10.1016/j.jcv.2020.104500.  
282 Epub 2020 Jun 8. PMID: 32585619; PMCID: PMC7278630.
- 283 15. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. Considerations for diagnostic COVID-19  
284 tests. *Nat Rev Microbiol.* 2021 Mar;19(3):171-183. doi: 10.1038/s41579-020-00461-z. Epub 2020 Oct 14.  
285 PMID: 33057203; PMCID: PMC7556561.

- 286 16. European Centre for Disease Prevention and Control. Options for the use of rapid antigen detection  
287 tests for COVID-19 in the EU/EEA – first update. 2021. Available at:  
288 <https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid-19-eueea-first->  
289 update
- 290 17. Gunell M, Antikainen P, Porjo N, Irjala K, Vakkila J, Hotakainen K, Kaukoranta SS, Hirvonen JJ, Saha K,  
291 Manninen R, Forsblom B, Rantakokko-Jalava K, Peltola V, Koskinen JO, Huovinen P. Comprehensive real-  
292 time epidemiological data from respiratory infections in Finland between 2010 and 2014 obtained from an  
293 automated and multianalyte mariPOC® respiratory pathogen test. *Eur J Clin Microbiol Infect Dis*. 2016  
294 Mar;35(3):405-13. doi: 10.1007/s10096-015-2553-0. Epub 2016 Jan 6. PMID: 26740322; PMCID:  
295 PMC7088327.
- 296 18. Koskinen JM, Antikainen P, Hotakainen K, Haveri A, Ikonen N, Savolainen-Kopra C, Sundström K,  
297 Koskinen JO. Clinical validation of automated and rapid mariPOC SARS-CoV-2 antigen test. *Sci Rep*. 2021 Oct  
298 13;11(1):20363. doi: 10.1038/s41598-021-99886-6. PMID: 34645929; PMCID: PMC8514458.
- 299 19. Suomen standardoimisliitto SFS. SFS-EN ISO 15189/Korjaus:2017. Lääketieteelliset laboratoriot. Laatu  
300 ja pätevyyttä koskevat vaatimukset. Available at:  
301 <https://sales.sfs.fi/fi/index/tuotteet/SFS/CENISO/ID2/1/240842.html.stx>
- 302 20. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S, Schneider J,  
303 Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette  
304 JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel  
305 coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020 Jan;25(3):2000045. doi: 10.2807/1560-  
306 7917.ES.2020.25.3.2000045. Erratum in: *Euro Surveill*. 2020 Apr;25(14): Erratum in: *Euro Surveill*. 2020  
307 Jul;25(30): Erratum in: *Euro Surveill*. 2021 Feb;26(5): PMID: 31992387; PMCID: PMC6988269.

- 308 21. MedCalc Software Ltd. Diagnostic test evaluation calculator.  
309 [https://www.medcalc.org/calc/diagnostic\\_test.php](https://www.medcalc.org/calc/diagnostic_test.php) (Version 20.027; accessed March 16, 2022)
- 310 22. Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, Dittrich S, Emperador D, Takwoingi Y,  
311 Cunningham J, Beese S, Domen J, Dretzke J, Ferrante di Ruffano L, Harris IM, Price MJ, Taylor-Phillips S,  
312 Hooft L, Leeflang MM, McInnes MD, Spijker R, Van den Bruel A; Cochrane COVID-19 Diagnostic Test  
313 Accuracy Group. Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2  
314 infection. *Cochrane Database Syst Rev*. 2021 Mar 24;3(3):CD013705. doi:  
315 [10.1002/14651858.CD013705.pub2](https://doi.org/10.1002/14651858.CD013705.pub2). PMID: 33760236; PMCID: PMC8078597.
- 316 23. Mardian Y, Kosasih H, Karyana M, Neal A, Lau CY. Review of Current COVID-19 Diagnostics and  
317 Opportunities for Further Development. *Front Med (Lausanne)*. 2021 May 7;8:615099. doi:  
318 [10.3389/fmed.2021.615099](https://doi.org/10.3389/fmed.2021.615099). PMID: 34026773; PMCID: PMC8138031.
- 319 24. Brümmer LE, Katzenschlager S, Gaeddert M, Erdmann C, Schmitz S, Bota M, Grilli M, Larmann J,  
320 Weigand MA, Pollock NR, Macé A, Carmona S, Ongarello S, Sacks JA, Denkinger CM. Accuracy of novel  
321 antigen rapid diagnostics for SARS-CoV-2: A living systematic review and meta-analysis. *PLoS Med*. 2021  
322 Aug 12;18(8):e1003735. doi: [10.1371/journal.pmed.1003735](https://doi.org/10.1371/journal.pmed.1003735). Erratum in: *PLoS Med*. 2021 Oct  
323 13;18(10):e1003825. PMID: 34383750; PMCID: PMC8389849.
- 324 25. Lefever S, Indevuyt C, Cuypers L, Dewaele K, Yin N, Cotton F, Padalko E, Oyaert M, Descy J, Cavalier E,  
325 Van Ranst M, André E, Lagrou K, Vermeersch P; Royal Belgian Society of Laboratory Medicine. Comparison  
326 of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-  
327 19 in Symptomatic and Asymptomatic Outpatients. *J Clin Microbiol*. 2021 Jun 18;59(7):e0037421. doi:  
328 [10.1128/JCM.00374-21](https://doi.org/10.1128/JCM.00374-21). Epub 2021 Jun 18. PMID: 33849953; PMCID: PMC8218764.
- 329 26. Peña M, Ampuero M, Garcés C, Gaggero A, García P, Velasquez MS, Luza R, Alvarez P, Paredes F,  
330 Acevedo J, Farfán MJ, Solari S, Soto-Rifo R, Valiente-Echeverría F. Performance of SARS-CoV-2 rapid antigen

- 331 test compared with real-time RT-PCR in asymptomatic individuals. *Int J Infect Dis.* 2021 Jun;107:201-204.  
332 doi: 10.1016/j.ijid.2021.04.087. Epub 2021 May 1. PMID: 33945868; PMCID: PMC8088036.
- 333 27. Baro B, Rodo P, Ouchi D, Bordoy AE, Saya Amaro EN, Salsench SV, Molinos S, Alemany A, Ubals M,  
334 Corbacho-Monné M, Millat-Martinez P, Marks M, Clotet B, Prat N, Estrada O, Vilar M, Ara J, Vall-Mayans M,  
335 G-Beiras C, Bassat Q, Blanco I, Mitjà O. Performance characteristics of five antigen-detecting rapid  
336 diagnostic test (Ag-RDT) for SARS-CoV-2 asymptomatic infection: a head-to-head benchmark comparison. *J*  
337 *Infect.* 2021 Jun;82(6):269-275. doi: 10.1016/j.jinf.2021.04.009. Epub 2021 Apr 18. PMID: 33882299;  
338 PMCID: PMC8053403.
- 339 28. Hirotsu Y, Maejima M, Shibusawa M, Nagakubo Y, Hosaka K, Amemiya K, Sueki H, Hayakawa M,  
340 Mochizuki H, Tsutsui T, Kakizaki Y, Miyashita Y, Yagi S, Kojima S, Omata M. Comparison of automated SARS-  
341 CoV-2 antigen test for COVID-19 infection with quantitative RT-PCR using 313 nasopharyngeal swabs,  
342 including from seven serially followed patients. *Int J Infect Dis.* 2020 Oct;99:397-402. doi:  
343 10.1016/j.ijid.2020.08.029. Epub 2020 Aug 12. PMID: 32800855; PMCID: PMC7422837.
- 344 29. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jo WK, Tscheak P,  
345 Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C. Comparison of seven commercial SARS-  
346 CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study. *Lancet Microbe.* 2021  
347 Jul;2(7):e311-e319. doi: 10.1016/S2666-5247(21)00056-2. Epub 2021 Apr 7. PMID: 33846704; PMCID:  
348 PMC8026170.
- 349 30. Toptan T, Eckermann L, Pfeiffer AE, Hoehl S, Ciesek S, Drosten C, Corman VM. Evaluation of a SARS-CoV-  
350 2 rapid antigen test: Potential to help reduce community spread? *J Clin Virol.* 2021 Feb;135:104713. doi:  
351 10.1016/j.jcv.2020.104713. Epub 2020 Dec 5. PMID: 33352470; PMCID: PMC7832367.
- 352



353

354 **Figure 1.** Correlation of Ct values of RT-PCR method and mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test among  
 355 symptomatic (black dots) and asymptomatic (empty dots) subjects.

356

357 **Table 1.** Demographic data on the population included in the mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test  
 358 evaluation study

| Demographic data        | Female     | Male       |
|-------------------------|------------|------------|
| Sex distribution (%)    | 575 (59.8) | 387 (40.2) |
| Median age              | 40.9 years | 39.2 years |
| Age distribution        | 4-81 years | 2-81 years |
| <18 year of age (%)     | 9 (0.9)    | 20 (2.1)   |
| >65 years of age (%)    | 30 (3.1)   | 20 (2.1)   |
| SARS-CoV-2 positive (%) | 22 (47.8)  | 24 (52.2)  |

359

360



361 **Table 2.** Clinical sensitivity and 95% confidence intervals of mariPOC<sup>®</sup> SARS-CoV-2 rapid antigen test among  
 362 symptomatic subjects at 20 minutes (preliminary) and 55 minutes (final) outcome in correlation to Ct values  
 363 of the reference RT-PCR method.

364

|                         |        | mariPOC <sup>®</sup> positives |                | PCR positives | mariPOC <sup>®</sup> Sensitivity (95% CI) |                    |
|-------------------------|--------|--------------------------------|----------------|---------------|---|--------------------|
|                         |        | 20 min outcome                 | 55 min outcome |               | 20 minutes outcome                        | 55 minutes outcome |
| <b>Cohort 1</b>         | Ct <30 | 17                             | 18             | 18            | 94.4% (72.7-99.9%)                        | 100.0% (81.5-100%) |
|                         | Ct <33 | 17                             | 18             | 20            | 85.0% (62.1-96.8%)                        | 90.0% (68.3-98.8%) |
|                         | Ct <40 | 17                             | 18             | 23            | 73.9% (51.6-89.8%)                        | 78.3% (56.3-92.5%) |
| <b>Cohort 2</b>         | Ct <30 | 13                             | 15             | 16            | 81.3% (54.4-96.0%)                        | 93.8% (69.8-99.8%) |
|                         | Ct <33 | 13                             | 15             | 17            | 76.5% (50.1-93.2%)                        | 88.2% (63.6-98.5%) |
|                         | Ct <40 | 13                             | 15             | 17            | 76.5% (50.1-93.2%)                        | 88.2% (63.6-98.5%) |
| <b>Cohort 1 &amp; 2</b> | Ct <30 | 30                             | 33             | 34            | 88.2% (72.6-96.7%)                        | 97.1% (84.7-99.9%) |
|                         | Ct <33 | 30                             | 33             | 37            | 81.1% (64.8-92.0%)                        | 89.2% (74.6-97.0%) |
|                         | Ct <40 | 30                             | 33             | 40            | 75.0% (58.8-87.3%)                        | 82.5% (67.2-92.7%) |

365

366